Sponsored by CeloNova BioSciences, Inc.
Article | September/October 2020
News | 10.17.20
COBRA-REDUCE Evaluates Shorter Duration DAPT After PCI With Nano-Coated Coronary Stent
October 17, 2020—The results of the COBRA-REDUCE trial demonstrated that for patients undergoing percutaneous coronary intervention (PCI) who also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual antiplatelet therapy (DAPT) did not reduce bleeding or establish noninferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard 3- or 6-month DAPT therapy.
News | 10.15.20
Shorter DAPT Regimen With Abbott's Xience V DES Is Noninferior to Standard DAPT for Ischemic Events
October 15, 2020—Results from the XIENCE 90/28 clinical trials presented by Roxana Mehran, MD, at TCT Connect have shown that a shorter course of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was noninferior to standard DAPT up to 12 months.
News | 10.14.20
Meta-Analysis Examines Mortality and Bleeding Rates for Bivalirudin Versus Heparin in Patients With MI
October 14, 2020—In a presentation at TCT Connect, an individual patient-data pooled analysis comparing the use of bivalirudin versus heparin in heart attack patients undergoing percutaneous coronary intervention (PCI) found that bivalirudin use was associated with similar overall rates of 30-day mortality across all heart attack patients, but lower rates of serious bleeding events.
News | 10.01.20
FDA Approves Expanded Indication for Medtronic’s Resolute Onyx DES for 1-Month DAPT in High-Bleeding-Risk Patients
October 1, 2020—Medtronic announced it has received FDA approval for new 1-month dual antiplatelet therapy (DAPT) labeling with an expanded indication for patients at high bleeding risk (HBR) implanted with the company’s Resolute Onyx drug-eluting stent (DES) in the United States.
News | 09.15.20
FDA Grants Fast Track Designation for Jardiance to Prevent Heart Failure in Patients After Acute MI
September 15, 2020—Boehringer Ingelheim and Eli Lilly and Company jointly announced that the FDA has granted Fast Track designation for the development of Jardiance (empagliflozin, an SGLT2 inhibitor) to prevent hospitalization for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction (MI).
News | 08.30.20
POPular TAVI Study Compares Antithrombotic Strategies After Valve Replacement
August 30, 2020—Findings from the POPular TAVI trial challenge current guideline recommendations on antiplatelet treatment after transcatheter aortic valve replacement (TAVR) in patients not taking oral anticoagulation, according to the European Society of Cardiology (ESC).
News | 08.30.20
Impact of Angina Drug Trimetazidine Evaluated After Successful PCI Revascularization
August 30, 2020—Trimetazidine administered after a successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, concluded investigators in the ATPCI trial, which was sponsored by I.R.I.S., Institut de Recherches Internationales Servier based in Suresnes, France.
News | 08.26.20
Mount Sinai Study Demonstrates Efficacy of Anticoagulants for COVID-19 Patients
August 26, 2020—The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai in New York, New York, announced the publication of findings from an observational study that showed that all regimens of anticoagulants were far superior to no anticoagulants in COVID-19 patients.
News | 06.05.20
CE Mark Approved for 1-Month DAPT Indication for High Bleeding Risk Patients Treated With Medtronic’s Resolute Onyx DES
June 5, 2020—Medtronic announced it has received European CE Mark approval for a 1-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx drug-eluting stent (DES).
News | 06.01.20
FDA Approves AstraZeneca’s Brilinta to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients With CAD
June 1, 2020—AstraZeneca announced FDA approval for Brilinta (ticagrelor) to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).
News | 05.29.20
Analysis of LEADERS FREE Supports Similar PCI Treatment in Women as in Men With High Bleeding Risk
May 29, 2020—The American College of Cardiology announced a recently published study that demonstrated that women with high bleeding risk should not be denied the benefits of percutaneous coronary intervention (PCI) when indicated and that bleeding avoidance strategies should be uniformly adopted for all patients, especially in women.
News | 05.14.20
REDUCE-IT REVASC Analyses Shows Icosapent Ethyl Significantly Reduced Revascularizations in Statin Patients
May 14, 2020—Findings from the REDUCE-IT REVASC analyses presented as late-breaking science during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions Virtual Conference held May 14–16 revealed that for statin-treated patients with elevated triglycerides and increased cardiovascular risk, icosapent ethyl significantly reduced first and subsequent revascularizations compared with placebo.
News | 05.06.20
News | 05.04.20
Large-Scale FOURNIER Study Supports Neurocognitive Safety of Evolocumab Plus Statin to Achieve Very Low LDL-C
May 4, 2020—The American College of Cardiology (ACC) announced that 2-year follow-up data from the entire 22,655-patient cohort of the FOURIER study confirm the neurocognitive safety of very low low-density lipoprotein cholesterol (LDL-C) levels in heart disease patients taking evolocumab in addition to a statin.
News | 04.27.20
EARLY Trial Evaluates Optimal Timing of Intervention in NSTE-ACS Without Pretreatment
April 27, 2020—Findings from the EARLY randomized trial comparing a delayed versus a very early invasive strategy in patients with non–ST-segment elevation acute coronary syndromes (NSTE-ACS) without pretreatment were published by Gilles Lemesle, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2020;13:907–917).
News | 03.30.20
Subanalysis of TWILIGHT Trial Shows Benefit of Ticagrelor Without Aspirin in Patients With Diabetes After PCI
March 30, 2020—Patients with diabetes who stopped taking aspirin 3 months after the insertion of a coronary stent and then took the antiplatelet medication ticagrelor alone for 1 year had fewer episodes of bleeding and no increase in heart attacks, stroke, or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for 1 year.
News | 03.30.20
TICO Study Shows Benefit for Ticagrelor Alone in Patients With ACS After PCI
March 30, 2020—At the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC), Yangsoo Jang, MD, presented data from the TICO study demonstrating that patients with acute coronary syndrome (ACS) who stopped taking aspirin 3 months after the insertion of a coronary stent and then took ticagrelor alone for 9 months had fewer episodes of bleeding and no increase in heart attacks, stroke, or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.